about
Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trialsEfficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults.Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza.Evaluation of recent New Vaccine Surveillance Network data regarding respiratory syncytial virus hospitalization rates in US preterm infantsA survey of pediatricians' attitudes regarding influenza immunization in childrenRespiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.Burden of paediatric influenza in Western Europe: a systematic review.Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.Current experience with school-located influenza vaccination programs in the United States: a review of the medical literature.Influenza vaccination of parents and guardians by US pediatriciansThe Underrecognized Burden of Respiratory Syncytial Virus Among Infants Presenting to US Emergency DepartmentsTrends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.Effects of Chronologic Age and Young Child Exposure on Respiratory Syncytial Virus Disease among US Preterm Infants Born at 32 to 35 Weeks Gestation.The safety and efficacy of live attenuated influenza vaccine in young children with asthma or prior wheezingRespiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses.Live attenuated influenza vaccine in children.Maternal outcomes among pregnant women receiving live attenuated influenza vaccine.Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age.The healthcare and societal burden associated with influenza in vaccinated and unvaccinated European and Israeli children.The impact of school-located influenza vaccination programs on student absenteeism: a review of the U.S. literature.A multi-season national estimate of adult influenza vaccination by U.S. office-based pediatricians, 2006-2011.The rationale for quadrivalent influenza vaccines.Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children.Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children during the 2014-2015 season.A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.A systematic review of the efficacy of live attenuated influenza vaccine upon revaccination of children.Association of vaccine handling conditions with effectiveness of live attenuated influenza vaccine against H1N1pdm09 viruses in the United States.Safety of quadrivalent live attenuated influenza vaccine in subjects aged 2-49years.Receipt of palivizumab before birth hospitalization discharge among preterm infants in the United States.Factors associated with increased vaccination in 2009 H1N1 school-located influenza vaccination programsChronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States.Statistical Power to Detect an Association Between Guideline-based Palivizumab Administration and Hospitalizations for Respiratory Syncytial Virus InfectionsGenetic sequence analysis of influenza viruses and illness severity in ill children previously vaccinated with live attenuated or inactivated influenza vaccine.Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age.Insurance Status and the Risk of Severe Respiratory Syncytial Virus Disease in United States Preterm Infants Born at 32-35 Weeks Gestational Age.SENTINEL1: An Observational Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.A population-weighted, condition-adjusted estimate of palivizumab efficacy in preventing RSV-related hospitalizations among US high-risk children.The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials.Concomitant administration of seasonal trivalent and pandemic monovalent H1N1 live attenuated influenza vaccines
P50
Q28748654-F8085DFF-C0E6-4034-8A5E-B07FD4B60A27Q30226435-B31335A7-3113-4DFB-A33B-1D2B94A14D35Q30377205-A4A774F4-D5DE-4E8E-9C25-968462BDCFF6Q31047460-176C254F-6C8D-480E-BE98-AA31B13654BDQ33404461-317EA86B-D2D4-41E5-9DD0-CC78E278768DQ33630047-5BCAD76B-F6A9-4DC4-8FE2-A36CDA342E16Q34475023-291DD941-9AB1-4051-B62B-3AFEACF69666Q34801986-1A88A765-8245-4D6E-9B6C-34911F828214Q35194820-034B8868-47C7-4A98-A731-7156223A5BB5Q35194841-59871522-FE05-4FF9-84E9-5A57A44DF3A7Q35882296-CA8FA4AB-8FFF-4842-B198-7A06921C13AFQ35980935-0C1A21B0-646C-4C33-B9CD-3B59D2D9C680Q36206766-BD7BDE3D-E31E-48A2-A150-F7D3737D95DEQ36275382-F66030BB-394B-4E3D-8E15-78160ED4DF13Q36295566-685CAEE5-B49A-4EB6-B07E-2C0B26A2BE58Q36630530-93BE1642-6C72-48E5-8D66-EF9AAE02794CQ37086850-E4833F92-E63B-48E1-A915-F129FE4039B6Q37087100-BA5802E9-209A-4DF6-9837-93D110D69268Q37636225-F5BAC06D-74EC-4F1F-8BF2-9AE2BD437D67Q37809656-1222C16D-065E-4F8A-8DE6-376192F4D791Q37955313-12F4E8DE-E86C-4416-A672-6980C529A014Q37976542-AD55EE8D-6380-4325-BBF1-F9EF3E8C3734Q38059737-49F6F303-4781-4AF6-812C-E0121A5C168EQ38346472-2930CCED-1D51-47C8-A7FC-B9BC13CF354AQ38378102-7D7967E2-5E0A-473B-91A2-C95CF4A9074FQ38492992-275CEFCC-427E-4C21-BBCD-1496083115CEQ38692107-85575DC0-CA04-4F3B-862A-5DCD4F9831A8Q38950526-FA6CE7E2-A083-4878-B834-730BD7887ABCQ38978356-24E3E6A7-4FF7-4A74-9AC5-FE859D581BE6Q39017757-60A1526C-6814-4ABF-928A-8F9F1E0D7335Q39191201-3CFD6975-3ECA-4C62-9E44-BA4F20622D2AQ40060039-2D52E903-E232-4B70-8C1C-DDBBFEE4815FQ40337141-7F3709BD-04F9-4174-B754-AC84C645816EQ40358535-14403A0F-BAEB-4740-8D48-B21C32171328Q40414736-AD9E4454-CEEE-4D81-85E7-03FBBAC17E7CQ40516621-269D1AA1-30A6-4E90-A6A3-BB012E5A19BDQ40732387-8FA3A73A-2753-48D3-AAE9-2CF6AC5E7C9EQ41612395-E6AB4866-0355-42B1-8F2B-ECA1F6C01C3BQ42265788-3119A031-E5C6-4C26-9CE5-F200B90E41CDQ42425426-35DEE258-99B5-40C8-B8EA-EE6884AD2603
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Christopher S Ambrose
@ast
Christopher S Ambrose
@en
Christopher S Ambrose
@es
Christopher S Ambrose
@nl
Christopher S Ambrose
@sl
type
label
Christopher S Ambrose
@ast
Christopher S Ambrose
@en
Christopher S Ambrose
@es
Christopher S Ambrose
@nl
Christopher S Ambrose
@sl
prefLabel
Christopher S Ambrose
@ast
Christopher S Ambrose
@en
Christopher S Ambrose
@es
Christopher S Ambrose
@nl
Christopher S Ambrose
@sl
P106
P21
P31
P496
0000-0003-4175-7336